Cronos Stock Based Compensation To Revenue from 2010 to 2024

CRON Stock

CAD 2.79 0.08 2.95%

Cronos Stock Based Compensation To Revenue yearly trend continues to be very stable with very little volatility. Stock Based Compensation To Revenue is likely to drop to 0.1. Stock Based Compensation To Revenue is a metric that compares the total value of stock-based compensation granted by Cronos Group to its total revenue, indicating how much of the revenue is used to compensate employees with stock options or awards. View All Fundamentals

Stock Based Compensation To Revenue

First Reported

2010-12-31

Previous Quarter

0.10051467

Current Value

0.0955

Quarterly Volatility

0.18996662

Credit Downgrade

Yuan Drop

Covid

Check Cronos financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Cronos' main balance sheet or income statement drivers, such as Interest Expense of 27.2 M, Selling General Administrative of 43.8 M or Total Revenue of 91.6 M, as well as many indicators such as Price To Sales Ratio of 8.66, Dividend Yield of 0.0 or PTB Ratio of 0.69. Cronos financial statements analysis is a perfect complement when working with Cronos Valuation or Volatility modules.

This module can also supplement various Cronos Technical models . Check out the analysis of Cronos Correlation against competitors.

When determining whether Cronos Group offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Cronos' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Cronos Group Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Cronos Group Stock:

How To Invest In Cronos

Details

Is Cronos Stock a good investment?

Details

What is Cronos' Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out the analysis of Cronos Correlation against competitors.

You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.

Please note, there is a significant difference between Cronos' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cronos is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cronos' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Cronos Stock Based Compensation To Revenue from 2010 to 2024

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY